Studies of the Efficacy of Low-Dose Apatinib Monotherapy as Third-Line Treatment in Patients with Metastatic Colorectal Cancer and Apatinib’s Novel Anticancer Effect by Inhibiting Tumor-Derived Exosome Secretion

Studies of the Efficacy of Low-Dose Apatinib Monotherapy as Third-Line Treatment in Patients with Metastatic Colorectal Cancer and Apatinib’s Novel Anticancer Effect by Inhibiting Tumor-Derived Exosome Secretion

Antiangiogenic therapy is an important treatment strategy for metastatic colorectal cancer (mCRC). We carried out a clinical study of low-dose apatinib (250 mg) monotherapy as a third-line treatment in patients with mCRC and assessed its efficacy and safety. It demonstrated that low-dose apatinib ha...

Full description

Bibliographic Details
Main Authors: Lingying Zhao, Qiang Yu, Chunyi Gao, Jingzhou Xiang, Bowen Zheng, Yujie Feng, Runyang Li, Wenqing Zhang, Xiaoting Hong, Yan-yan Zhan, Li Xiao, Tianhui Hu
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Cancers
Subjects:
low-dose
apatinib
colorectal cancer
transcriptome sequencing
exosome secretion
Online Access:https://www.mdpi.com/2072-6694/14/10/2492

Internet

https://www.mdpi.com/2072-6694/14/10/2492

Similar Items